The current practice in Germany and Austria, and the safety and efficacy of botulinum toxin type A (BoNT-A; Dysport) in the treatment of patients with post-stroke arm spasticity (with no fixed upper-limb contractures), were assessed in this observational prospective non-interventional study. One treatment cycle was documented with assessments at baseline, approximately week 4 (optional), and approximately week 12. Pattern of spasticity, treatment goal, safety and efficacy were recorded. Overall response and goal achievement was rated on a 4-point scale ('no goal achievement', 'goal achievement', 'good goal achievement', 'best goal achievement'). In total, 409 patients were included and 99% assigned to one of five arm-spasticity patterns. Therapy goals included reduced muscle tone (92.6%), physiotherapy or occupational therapy support (63.8%), increased range of motion (61.8%), pain reduction (58.9%), facilitation of care or hygiene (55.7%), and functional improvement (17.0%). Goals were achieved in 84% of patients. The following factors had the most potential as predictors of treatment outcome: pretreatment; time since onset of spasticity; pattern of arm spasticity. Mean Dysport dose was 728 U and an inverse dose-response relationship was observed. Treatment was well tolerated. 500-1000 U was a safe and effective treatment for post-stroke arm spasticity in this post-marketing evaluation.
Introduction
An ischemic or hemorrhagic stroke can cause damage to the brain tissue and, if this occurs in the motor cortex or major motor pathways, it can result in motor disorders. A typical syndrome arising from this damage is the upper motor neuron syndrome (UMNS), including positive and negative features, one of which can be spasticity of the upper and lower limb muscles. This often causes difficulties with activities of daily living, creating a long-term need for treatment. Only 5% of stroke patients with paresis and spasticity of the arm regain useful function, and prospects of full recovery after 3 months are negligible [1] . Depending on the localization of the lesion, different muscle groups are affected by stroke. Although stroke is one of the most common causes of spasticity, other forms of brain injury can also result in spastic arm postures.
The combination of spastic muscles affected constrains the affected arm in a specific posture or movement pattern, and five typical arm spasticity patterns can be distinguished ( Fig. 1) [2] .
Of the numerous treatments that are currently available for poststroke upper limb spasticity, little functional benefit has been demonstrated [reviewed in 3] . Pharmacologic agents include those that act on ion flux in the central nervous system (CNS; e.g. baclofen, diazepam, orphenadrine citrate) and musculature (e.g. dantrolene). However, these compounds are relatively non-selective, commonly evoking relevant adverse reactions in the absence of any significant efficacy [4, 5] . Other pharmacologic agents including monoamines, drugs acting on excitatory amino acids, cannabinoids, and neuromuscular blocking agents, have not been shown to produce any significant benefits for patients [6] . Several alternative approaches that have shown inconsistent results include injection of alcohol and phenol into motor nerve branches or peripheral nerves [7] , numerous physiotherapy techniques [reviewed in 3], and procedures involving electrical stimulation of muscles and peripheral nerves [8] .
Botulinum neurotoxin (BoNT) reduces muscle tone by selectively targeting peripheral nerve endings. By selectively cleaving synaptosomal-associated protein 25 (SNAP-25), BoNT type A (BoNT-A) inhibits release of the neurotransmitter acetylcholine at presynaptic nerve endings [9] . As such, BoNT-A is established as an effective and well-tolerated treatment for patients with post-stroke arm spasticity [5, 10] , and treatment recommendations for BoNT-A with respect to target muscles and doses have been drawn up based on the five arm spasticity patterns. There are currently three commercially available preparations of type A toxins: Dysport® (abobotulinumtoxinA; Ipsen), Botox® (onabotulinumtoxinA; Allergan Incorporated), and Xeomin® (incobotulinumtoxinA; Merz Pharmaceuticals GmbH). Dysport is approved in Germany and Austria for the symptomatic treatment of post-stroke arm spasticity in adults [11] .
A prospective multi-center study was conducted to assess current practice in Germany and Austria and to evaluate safety and efficacy of the treatment of patients with arm spasticity with Dysport. In this study, response to treatment was assessed based on whether or not patients met their goals of treatment assigned at baseline. Patientcentered assessment is important for conditions such as spasticity, where improvement in patient function and outcomes are the main aims of treatment.
Methods

Study design and patients
This was a prospective open-label non-interventional multi-center post-marketing surveillance study, conducted in 85 centers in Germany and Austria. Male and female outpatients aged at least 18 years with arm spasticity caused by apoplexia, scheduled to receive or already receiving treatment with BoNT-A were eligible for inclusion. Patients were excluded if they had fixed contractures at the upper limb or contraindications for Dysport therapy, as per the Summary of Product Characteristics [11] ; no further exclusion criteria were defined.
Study treatment
All patients received a single injection treatment with Dysport to the affected arm in accordance with the recommendations given in the German or Austrian Summary of Product Characteristics. In addition, the study protocol provided recommendations for Dysport dose and muscle selection for each of the five typical arm spasticity patterns (I to V; Fig. 1 ). Dosing, injection protocol, and target muscles were based entirely on the judgment of the physician, who were not required to follow these pattern-specific recommendations. Control of injection (palpation, electromyography [EMG] , stimulation, or ultrasound) was also at the physicians' discretion. Concomitant therapies were permitted throughout the study e.g. physiotherapy or occupational therapy. One treatment cycle was documented with assessments at baseline, an optional intermediate visit around week 4, and closing visit at approximately week 12.
Assessments
At baseline, patients and physicians selected one or several realistic individual therapy goals for treatment from a list. These goals included tone reduction, improvement of mobility, pain reduction, facilitation of care/hygiene, support of physiotherapy and occupational therapy, and individual functional gain. There were three options available to the physician for assessing the achievement of the initially chosen therapy goal: 'fully achieved', 'partially achieved', and 'not achieved', evaluated at weeks 4 and 12.
Prior to data analysis, patients were classified into one of four groups based on goal achievement status:
• 'Goal Achieved' (GA) group if no severe related adverse events (AEs)
were recorded and the therapy was deemed effective.
• 'Good GA' group if no severe related AEs were recorded, the therapy was deemed effective, and 50% of the patient's treatment goals were fully achieved.
• 'Best GA' group if no severe related AEs were recorded, the therapy was deemed effective, and 100% of the patient's treatment goals were fully achieved.
• If none of these criteria were met, the patient was as allocated to the 'No GA' group.
Any patient experiencing a severe related AE would be considered a non-responder, regardless of response.
At the end of observation phase, 84% of patients achieved their predefined goals: 54% 'GA', 18% 'Good GA', 12% 'Best GA'. The remaining 16% of patients were allocated to the 'No GA' group.
Physicians and patients were asked to assess the overall effectiveness of the treatment at reducing symptoms on a 3-point scale as 'worse', 'no effect', or 'better', and comment on how satisfied they were with the treatment ('very satisfied', 'satisfied', 'neither satisfied nor dissatisfied', 'dissatisfied', or 'very dissatisfied'). AEs and data on patients discontinuing therapy were also recorded.
Statistical analyses
Elementary descriptive statistical evaluation of all collected data was performed using SAS 9.1 for Windows. Only patients who attended all visits (initial visit, intermediate visit, and closing visit) were included in the assessment evaluation of achieved therapy goals. On the basis of this statistical analysis procedure, the predictive variables with influence on the affiliation with a GA were to be identified. Stepwise logistic regression analysis (SLRA) was performed to identify factors influencing GA; this analysis was considered exploratory. Most of the factors included were categorical factors, therefore a logistic RA was used instead of linear RA. Independent factors included in the model were:
• dose (three classes: b 500, 500-1000, ≥1001 U); For the stepwise regression analysis, only patients with documented valid data for all predictive variables were included (n = 284; 70.0%). Three different regression analyses were performed: GA; good GA; best GA. No correlation or principal component analysis was performed.
Results
Patient disposition and demographic characteristics
Eighty-five centers provided data for 409 patients. Three patients were subsequently excluded from the analyses, due to missing data or being under 18 years of age. Intermediate visits were attended by 317 patients, at approximately 4 weeks (mean 36.2 days), and 391 patients attended the final visit, at approximately 12 weeks post-treatment; the mean time period of observation was 97.4 days. Complete attendance to all study visits was achieved by 307 patients, who were subsequently included in the evaluation assessing achievement of therapy goals. Dysport therapy was continued after completion of the study by 334 patients. The main reasons for not continuing Dysport treatment were: persistent effect at time-point for re-treatment (43.6%), patient request (25.6%), and missing effect (15.4%).
Patient demographics are summarized in Table 1 . The median time between stroke and spasticity was 7.1 months. BoNT-A injections had previously been received by 50% of patients (mean, 7.9 cycles; range, 1 to 46). The majority of patients received concomitant therapy during the treatment cycle: 93.8% (381/406) of patients received physiotherapy and 56.4% (229/406) of patients received occupational therapy. Twenty-nine percent (n = 119) received oral therapy for spasticity; Baclofen was recorded in 45.4% of cases (54/119). Aside from oral therapeutic agents for the treatment of further concomitant diseases, other physical therapies such as massage, lymphatic drainage, water exercise therapy, respiration therapy or logopedics were only rarely recorded, 6.2% (25/406) in total.
The therapy goals most frequently mentioned were reduced muscle tone (92.6%), support of physiotherapy and occupational therapy (63.8%), improvement of mobility (61.8%), pain reduction (58.9%), facilitation of care or hygiene (55.7%), and improvement of functioning (17.0%). The average number of goals per patient was 3.6.
Duration of spasticity, defined by onset of spasticity prior to inclusion in this study, varied among patients categorized by GA, with the longest duration reported for patients with best GA (mean 7.2 years) followed by GA or no GA (6.5 years), and good GA (5.6 years).
Pattern distribution
Ninety-nine percent of the patients could be allocated to one of the five pre-defined typical arm spasticity patterns: 34% to pattern I, 36% to pattern III and 23% to pattern IV, and 3% each to pattern II and V. The majority of patients (77%) presented a spastic flexed hand.
Treatment and dosing
The mean Dysport dose was 728 U (100-2300 U). In 73.6% of patients, a dose between 500 and 1000 U Dysport was injected, 16.9% of patients received less than 500 U Dysport, and 9.5% received more than 1000 U Dysport. The mean dose of Dysport across the five different arm spasticity patterns was as follows: pattern I, 707 U; pattern II, 575 U; pattern III, 711 U; pattern IV, 799 U; and pattern V, 747 U.
An inverse relationship between dose and GA was observed (Fig. 2) . Thus, the lowest average dose of Dysport (651 U) was administered to the best GA group, with higher doses being used in those with good GA (677 U), GA (733 U) and no GA (823 U). Injection of targeted muscle was controlled for by palpation (71.4%), EMG (50.5%), stimulation (12.1%), and ultrasound (7.6%) [more than one method may have been used]. In 37.4% of cases, a technical method was used in conjunction with palpation. A positive relationship between the use of palpation and an injection-guided technique (EMG, stimulation or ultrasound) and GA was observed; the higher the GA, the larger the percentage of patients with monitoring by at least one technical method and palpation (best GA group, 62%; good GA group, 40%; GA group, 37%; no GA, 17%).
Efficacy results
Overall, 84% (95% CI: 80-87%) of patients experienced a degree of GA (best GA, good GA, or GA) with Dysport therapy (Fig. 3) . The percentage of patients with 'GA' was broadly similar between the spasticity patterns.
The majority of patients also assessed their situation as 'better' at the intermediate visit (89.0%; 282/317) and closing visit (87.2%; 341/391). A total of 87.0% of patients were 'satisfied' with the Dysport treatment, with only 8.7% being 'dissatisfied'. The dissatisfaction was predominantly attributed to the lack of benefit from treatment.
A large percentage of the physicians documented improvement during the intermediate visit (94.6%; 300/317), as well as the closing visit (91.3%; 357/391). In 86.7% (339/391) of cases, the physicians were very or rather satisfied with the Dysport therapy. A few physicians were neither satisfied nor dissatisfied (5.4%) or expressed dissatisfaction with treatment (3.1%). Dissatisfaction was predominantly attributed to a missing effect of the therapy.
The goals of treatment determined at the first visit were fully or partially achieved in the majority of patients: the therapy goal of pain reduction was achieved in 94.7% of patients, tone reduction was achieved in 94.3%, improvement in administering physio-or occupational therapy was achieved in 93.0%, facilitation of care/hygiene was improved in 89.9%, and improvement in arm mobility was achieved in 89.2%.
In the SLRA based on GA, the four most influential factors of a positive GA were pre-treatment (whether the patients were de novo or had been previously treated with BoNT-A), time since spasticity onset, the spasticity pattern, and overall injection dose. Factors significantly predictive of good GA were patient status (pre-treated vs. naïve) (p b 0.01) and duration of spasticity (p = 0.03). Pattern of spasticity (p = 0.06), etiology of spasticity (p = 0.08), number of therapy goals (p = 0.12), and cumulative injection dose (p = 0.15) did not reach significance in the "Good GA" regression analysis.
Safety
A total of seven AEs were reported in 6/409 patients (1.5%); one was serious (sepsis) but not related to Dysport treatment. AEs related to therapy included weakness in the injected arm/hand (n = 3) and ptosis (n = 1), both of which can be regarded as expected due to the known effects of botulinum toxin. Edema (n = 1) and seizures (n = 1) were also reported and were assessed as not related to treatment with Dysport. Treatment was discontinued in two patients following an AE (arm weakness, n = 1; loss of remaining function, n = 1; neither were serious).
Discussion
This non-interventional study assessed the efficacy and safety of Dysport for the treatment of post-stroke arm spasticity. Dysport proved to be both effective and well tolerated. Response to Dysport was also rapid, with many patients experiencing improvement by the intermediate visit. Both physicians and patients rated the treatment as having a good effect. In addition to the high number of patients responding to treatment, Dysport administration resulted in a high number of patients achieving treatment goals set at baseline, demonstrating that improvements in spasticity translate into meaningful improvement in patientcentered outcomes. Thus, these data show that Dysport meets the expectations of treatment in a vast majority of patients suffering from arm spasticity. A very low rate of AEs and discontinuation were reported, supporting the good safety profile of Dysport. Observed related AEs were expected based on the known effects of BoNT-A [12] .
Given the patient population, it was not surprising that reduction in muscle tone was identified as the main goal of treatment in the majority of patients. Other important goals set by more than 50% of patients included improvement in administering physio-or occupational therapy, improvement of mobility, pain reduction, and facilitation of care or hygiene. Importantly, these goals were achieved in the majority of patients. Although functional improvement was specified as a treatment goal only in the minority of patients, this would be expected given the chronic nature of spasticity in this population; improvements in active function is a more common goal in the early stages of treatment, while improvement in passive function is more common in chronic 
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spasticity in order to facilitate activities such as dressing and personal hygiene [13] . This study shows dosages between 500 and 1000 U of Dysport for the treatment of arm spasticity seem to be adequate and well tolerated, in agreement with both controlled studies [14, 15] and data from retrospective analysis of long-term use [16] . The results of this study suggest that spasticity pattern II is treated with lower doses in clinical practice. It should be noted that an inverse relationship between dose and GA was observed in this study. There are several possible explanations for this observation. For example, lower doses may have permitted some degree of residual muscle tone for compensatory movement, thus leading to improved patient satisfaction. It is also possible that those with best GA may be familiar with the effects of treatment allowing more realistic prediction of outcomes, regardless of dose. It also cannot be ruled out that use of goal attainment to assess response to treatment is prone to error, resulting in this unexpected finding. Alternatively, other factors not included in the list of independent factors as severity of spasticity, may have influenced the findings. For example, patients receiving higher doses may have had more severe spasticity, which may have decreased the chance of functional improvement, despite administration of higher doses. Although the reasons for this finding are unclear, it is important to highlight that patients benefitted from treatment and use of patient-centered goals remains an important method of evaluating treatment outcomes for patients and clinicians.
In addition to confirming reports demonstrating clinical efficacy of Dysport in this indication, this study shows that current Dysport dosing used in clinical practice leads to a high level of patient and physician satisfaction with treatment. It should be noted that while dosing recommendations based on spasticity pattern were provided to clinicians, it is not known how closely physicians adhered to these guidelines, and this should be considered when interpreting the findings.
Exploratory analysis to identify potential factors associated with GA demonstrated that several patient factors (e.g. previous treatment status, duration of spasticity) were important in determining outcome. Importantly, factors under clinicians' control, namely total injection dose and injection control techniques, were potential predictors of outcome. This emphasizes the importance of arm pattern classification and corresponding treatment recommendation for guiding decisions on BoNT-A treatment in patients with arm spasticity. Arm pattern classification also provides common terminology and facilitates a quick and understandable information exchange with other physicians. The findings of this study indicate that the dose of Dysport administered is dependent on the arm spasticity pattern and may provide future guidance to physicians.
Conclusion
In conclusion, Dysport proved to be a safe and effective treatment for post-stroke arm spasticity in this post-marketing evaluation.
